SAT0499 Power Doppler Ulrasonographic Monitoring of Response to Treatment in Gout Patients

Background The accepted outcome measures for gout are seric urate, recurrent outbreaks, tophi regression and joint damage image. The Power Doppler ultrasound (PDUS) has demonstrated validity in the monitoring of treatment in other arthropathies, and it has been correlated with the presence of inflam...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A750-A751
Hauptverfasser: Peiteado Lopez, M. D., Villalba, A., De Miguel, E., Martin-Mola, E.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A751
container_issue Suppl 3
container_start_page A750
container_title Annals of the rheumatic diseases
container_volume 72
creator Peiteado Lopez, M. D.
Villalba, A.
De Miguel, E.
Martin-Mola, E.
description Background The accepted outcome measures for gout are seric urate, recurrent outbreaks, tophi regression and joint damage image. The Power Doppler ultrasound (PDUS) has demonstrated validity in the monitoring of treatment in other arthropathies, and it has been correlated with the presence of inflammatory activity. Objectives To evaluate the role of PDUS as a treatment monitoring tool in a cohort of gout patients. Methods In this 2 years longitudinal study, we prospectively evaluated patients with a clinical history suggestive of gout and at least one symptomatic flare in the last three months. Crystal identificaction by microscopy was made in all patients. Clinical and laboratory parameters were evaluated and treatment was adjusted to achieve an adequate disease control. In all visits (baseline, 6, 12 and 24 month) a second rheumatologist blinded to clinical data performed the ultrasound examination with a Logiq 9 equipment (General Electric Medical Systems, Milwaukee, WI, USA) with probe 9-14-MHz to scale grey and 5-7.5-MHz Doppler. Standardized examinations were carried out over four joints: first metatarsophalangeals (MTP) and knees (medial and lateral recesses); and the patellar tendons; and PD signal were scored. Mean and standard deviation was calculated for each parameter in the consecutive visits. The comparison between quantitative values ​​was performed by Student t test for paired samples. Sensitivity to change of the US was assessed by estimating the smallest detectable difference (SSD) in the Doppler total score. Results 24 consecutive patients (95.8% men) were included, with mean age of 60.8 (± 11 years), and mean disease duration of 10.3 years (IQR: 2-15). At baseline, 42, 71 and 50% were being treated with allopurinol, colchicine and NSAIDs, respectively. A significant decrease was observed in clinical and laboratory parameters, and also in the ultrasound Doppler signal (Table 1). The minimum detectable change at 2 years in Doppler score was 1.92, and it was lower than the difference between the baseline score and the score of the two years, which means that the detected change was independent of chance or measurement error. Despite an adequate disease control (62% of patients with serum urate
doi_str_mv 10.1136/annrheumdis-2013-eular.2223
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777912967</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008740771</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1657-7c30e26ece0547ee0703dcd44d121604fde7daf1ce0ba6f4fe93cc61ab07dcdc3</originalsourceid><addsrcrecordid>eNqVkLFOwzAQhi0EEqXwDpY6p9hxajdiqgoUpAIVTZmQLCe5tCmNHexEwMbCi_IkuBQhVqbT2d9_p_sQ6lHSp5TxU6W1XUFb5aULQkJZAO1G2X4YhmwPdWjEh_6Zk33UIYSwIIq5OERHzq19S4Z02EGP81FCojj-fP-YmRew-NzU9cbXxcYqZ7RZWlWvygzfGF02xpZ6iU2B78HVRjvAjcGJBdVUoBtcajwxbYNnqil9747RQaE2Dk5-ahctLi-S8VUwvZtcj0fTIKV8IAKRMQIhhwzIIBIARBCWZ3kU5TSknERFDiJXBfX_qeJFVEDMsoxTlRLhuYx1UW83t7bmuQXXyLVprfYrJRVCxDT0h3vqbEdl1jhnoZC1LStl3yQlcqtT_tEptzrlt0651enTwS5dugZef6PKPkk_Wwzk7cNYnotEMC7mknqe7_i0Wv9r0Rf81pIb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777912967</pqid></control><display><type>article</type><title>SAT0499 Power Doppler Ulrasonographic Monitoring of Response to Treatment in Gout Patients</title><source>BMJ Journals - NESLi2</source><creator>Peiteado Lopez, M. D. ; Villalba, A. ; De Miguel, E. ; Martin-Mola, E.</creator><creatorcontrib>Peiteado Lopez, M. D. ; Villalba, A. ; De Miguel, E. ; Martin-Mola, E.</creatorcontrib><description>Background The accepted outcome measures for gout are seric urate, recurrent outbreaks, tophi regression and joint damage image. The Power Doppler ultrasound (PDUS) has demonstrated validity in the monitoring of treatment in other arthropathies, and it has been correlated with the presence of inflammatory activity. Objectives To evaluate the role of PDUS as a treatment monitoring tool in a cohort of gout patients. Methods In this 2 years longitudinal study, we prospectively evaluated patients with a clinical history suggestive of gout and at least one symptomatic flare in the last three months. Crystal identificaction by microscopy was made in all patients. Clinical and laboratory parameters were evaluated and treatment was adjusted to achieve an adequate disease control. In all visits (baseline, 6, 12 and 24 month) a second rheumatologist blinded to clinical data performed the ultrasound examination with a Logiq 9 equipment (General Electric Medical Systems, Milwaukee, WI, USA) with probe 9-14-MHz to scale grey and 5-7.5-MHz Doppler. Standardized examinations were carried out over four joints: first metatarsophalangeals (MTP) and knees (medial and lateral recesses); and the patellar tendons; and PD signal were scored. Mean and standard deviation was calculated for each parameter in the consecutive visits. The comparison between quantitative values ​​was performed by Student t test for paired samples. Sensitivity to change of the US was assessed by estimating the smallest detectable difference (SSD) in the Doppler total score. Results 24 consecutive patients (95.8% men) were included, with mean age of 60.8 (± 11 years), and mean disease duration of 10.3 years (IQR: 2-15). At baseline, 42, 71 and 50% were being treated with allopurinol, colchicine and NSAIDs, respectively. A significant decrease was observed in clinical and laboratory parameters, and also in the ultrasound Doppler signal (Table 1). The minimum detectable change at 2 years in Doppler score was 1.92, and it was lower than the difference between the baseline score and the score of the two years, which means that the detected change was independent of chance or measurement error. Despite an adequate disease control (62% of patients with serum urate &lt;6) the Doppler signal persists in a high percentage of patients (67%). Conclusions PDUS is sensitive to change in monitoring the treatment of gout. The 1stMTP joint is the more useful site for US treatment monitoring. The Doppler signal persists despite adequate control of the disease. Disclosure of Interest None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2013-eular.2223</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A750-A751</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A750.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A750.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77343,77374</link.rule.ids></links><search><creatorcontrib>Peiteado Lopez, M. D.</creatorcontrib><creatorcontrib>Villalba, A.</creatorcontrib><creatorcontrib>De Miguel, E.</creatorcontrib><creatorcontrib>Martin-Mola, E.</creatorcontrib><title>SAT0499 Power Doppler Ulrasonographic Monitoring of Response to Treatment in Gout Patients</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background The accepted outcome measures for gout are seric urate, recurrent outbreaks, tophi regression and joint damage image. The Power Doppler ultrasound (PDUS) has demonstrated validity in the monitoring of treatment in other arthropathies, and it has been correlated with the presence of inflammatory activity. Objectives To evaluate the role of PDUS as a treatment monitoring tool in a cohort of gout patients. Methods In this 2 years longitudinal study, we prospectively evaluated patients with a clinical history suggestive of gout and at least one symptomatic flare in the last three months. Crystal identificaction by microscopy was made in all patients. Clinical and laboratory parameters were evaluated and treatment was adjusted to achieve an adequate disease control. In all visits (baseline, 6, 12 and 24 month) a second rheumatologist blinded to clinical data performed the ultrasound examination with a Logiq 9 equipment (General Electric Medical Systems, Milwaukee, WI, USA) with probe 9-14-MHz to scale grey and 5-7.5-MHz Doppler. Standardized examinations were carried out over four joints: first metatarsophalangeals (MTP) and knees (medial and lateral recesses); and the patellar tendons; and PD signal were scored. Mean and standard deviation was calculated for each parameter in the consecutive visits. The comparison between quantitative values ​​was performed by Student t test for paired samples. Sensitivity to change of the US was assessed by estimating the smallest detectable difference (SSD) in the Doppler total score. Results 24 consecutive patients (95.8% men) were included, with mean age of 60.8 (± 11 years), and mean disease duration of 10.3 years (IQR: 2-15). At baseline, 42, 71 and 50% were being treated with allopurinol, colchicine and NSAIDs, respectively. A significant decrease was observed in clinical and laboratory parameters, and also in the ultrasound Doppler signal (Table 1). The minimum detectable change at 2 years in Doppler score was 1.92, and it was lower than the difference between the baseline score and the score of the two years, which means that the detected change was independent of chance or measurement error. Despite an adequate disease control (62% of patients with serum urate &lt;6) the Doppler signal persists in a high percentage of patients (67%). Conclusions PDUS is sensitive to change in monitoring the treatment of gout. The 1stMTP joint is the more useful site for US treatment monitoring. The Doppler signal persists despite adequate control of the disease. Disclosure of Interest None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkLFOwzAQhi0EEqXwDpY6p9hxajdiqgoUpAIVTZmQLCe5tCmNHexEwMbCi_IkuBQhVqbT2d9_p_sQ6lHSp5TxU6W1XUFb5aULQkJZAO1G2X4YhmwPdWjEh_6Zk33UIYSwIIq5OERHzq19S4Z02EGP81FCojj-fP-YmRew-NzU9cbXxcYqZ7RZWlWvygzfGF02xpZ6iU2B78HVRjvAjcGJBdVUoBtcajwxbYNnqil9747RQaE2Dk5-ahctLi-S8VUwvZtcj0fTIKV8IAKRMQIhhwzIIBIARBCWZ3kU5TSknERFDiJXBfX_qeJFVEDMsoxTlRLhuYx1UW83t7bmuQXXyLVprfYrJRVCxDT0h3vqbEdl1jhnoZC1LStl3yQlcqtT_tEptzrlt0651enTwS5dugZef6PKPkk_Wwzk7cNYnotEMC7mknqe7_i0Wv9r0Rf81pIb</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Peiteado Lopez, M. D.</creator><creator>Villalba, A.</creator><creator>De Miguel, E.</creator><creator>Martin-Mola, E.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>SAT0499 Power Doppler Ulrasonographic Monitoring of Response to Treatment in Gout Patients</title><author>Peiteado Lopez, M. D. ; Villalba, A. ; De Miguel, E. ; Martin-Mola, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1657-7c30e26ece0547ee0703dcd44d121604fde7daf1ce0ba6f4fe93cc61ab07dcdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peiteado Lopez, M. D.</creatorcontrib><creatorcontrib>Villalba, A.</creatorcontrib><creatorcontrib>De Miguel, E.</creatorcontrib><creatorcontrib>Martin-Mola, E.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peiteado Lopez, M. D.</au><au>Villalba, A.</au><au>De Miguel, E.</au><au>Martin-Mola, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SAT0499 Power Doppler Ulrasonographic Monitoring of Response to Treatment in Gout Patients</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A750</spage><epage>A751</epage><pages>A750-A751</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background The accepted outcome measures for gout are seric urate, recurrent outbreaks, tophi regression and joint damage image. The Power Doppler ultrasound (PDUS) has demonstrated validity in the monitoring of treatment in other arthropathies, and it has been correlated with the presence of inflammatory activity. Objectives To evaluate the role of PDUS as a treatment monitoring tool in a cohort of gout patients. Methods In this 2 years longitudinal study, we prospectively evaluated patients with a clinical history suggestive of gout and at least one symptomatic flare in the last three months. Crystal identificaction by microscopy was made in all patients. Clinical and laboratory parameters were evaluated and treatment was adjusted to achieve an adequate disease control. In all visits (baseline, 6, 12 and 24 month) a second rheumatologist blinded to clinical data performed the ultrasound examination with a Logiq 9 equipment (General Electric Medical Systems, Milwaukee, WI, USA) with probe 9-14-MHz to scale grey and 5-7.5-MHz Doppler. Standardized examinations were carried out over four joints: first metatarsophalangeals (MTP) and knees (medial and lateral recesses); and the patellar tendons; and PD signal were scored. Mean and standard deviation was calculated for each parameter in the consecutive visits. The comparison between quantitative values ​​was performed by Student t test for paired samples. Sensitivity to change of the US was assessed by estimating the smallest detectable difference (SSD) in the Doppler total score. Results 24 consecutive patients (95.8% men) were included, with mean age of 60.8 (± 11 years), and mean disease duration of 10.3 years (IQR: 2-15). At baseline, 42, 71 and 50% were being treated with allopurinol, colchicine and NSAIDs, respectively. A significant decrease was observed in clinical and laboratory parameters, and also in the ultrasound Doppler signal (Table 1). The minimum detectable change at 2 years in Doppler score was 1.92, and it was lower than the difference between the baseline score and the score of the two years, which means that the detected change was independent of chance or measurement error. Despite an adequate disease control (62% of patients with serum urate &lt;6) the Doppler signal persists in a high percentage of patients (67%). Conclusions PDUS is sensitive to change in monitoring the treatment of gout. The 1stMTP joint is the more useful site for US treatment monitoring. The Doppler signal persists despite adequate control of the disease. Disclosure of Interest None Declared</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2013-eular.2223</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A750-A751
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777912967
source BMJ Journals - NESLi2
title SAT0499 Power Doppler Ulrasonographic Monitoring of Response to Treatment in Gout Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A09%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SAT0499%E2%80%85Power%20Doppler%20Ulrasonographic%20Monitoring%20of%20Response%20to%20Treatment%20in%20Gout%20Patients&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Peiteado%20Lopez,%20M.%20D.&rft.date=2013-06&rft.volume=72&rft.issue=Suppl%203&rft.spage=A750&rft.epage=A751&rft.pages=A750-A751&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2013-eular.2223&rft_dat=%3Cproquest_cross%3E4008740771%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777912967&rft_id=info:pmid/&rfr_iscdi=true